恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展

doi:10.11904/j.issn.1002-3070.2022.05.016

摘要/Abstract

摘要： T-DM1是由人源化单克隆抗体曲妥珠单抗通过连接子和细胞毒性药物DM1偶联形成的一种抗体-药物偶联物,综合了抗体的靶向性和细胞毒性药物的高效杀伤癌细胞特性,发挥双倍抗肿瘤效应的同时又降低了常规化疗药物的毒副反应。多项临床研究探索了T-DM1应用于晚期HER2阳性转移性乳腺癌的解救治疗以及早期HER2阳性乳腺癌的辅助化疗和新辅助化疗的有效性和耐受性,并展现出良好的临床应用前景。本文就T-DM1应用于HER2阳性乳腺癌的最新临床研究进展简要综述。

关键词: T-DM1, HER2阳性乳腺癌, 作用机制, 临床研究, 耐药机制

Abstract: Trastuzumab emtansine(T-DM1)is an antibody drug conjugate formed by the conjugation of humanized monoclonal antibody trastuzumab with cytotoxic drug DM1 through a linker,which integrates the targeting antibody and the high efficiency of cytotoxic drugs to kill cancer cells,exerts double anti-tumor effect and reduces the toxicity of conventional chemotherapeutic drugs.Several clinical studies have explored the effectiveness and tolerance of T-DM1 in rescue treatment of advanced HER2 positive metastatic breast cancer and adjuvant and neoadjuvant chemotherapy of early HER2 positive breast cancer,and shown a good clinical application prospects.This article briefly reviews the latest clinical research progress of T-DM1 in HER2 positive breast cancer.

Key words: Trastuzumab emtansine, HER2 positive breast cancer, Mechanisms of action, Clinical trials, Drug resistance mechanism

中图分类号:

R737.9

李智慧, 李志高. 恩美曲妥珠单抗T-DM1在HER2阳性乳腺癌中的研究进展[J]. 实用肿瘤学杂志, 2022, 36(5): 477-482.

LI Zhihui, LI Zhigao. Research progress of T-DM1 in treatment of HER2 positive breast cancer[J]. Journal of Practical Oncology, 2022, 36(5): 477-482.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2022.05.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2022/V36/I5/477

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Kunte S,Abraham J,Montero AJ.Novel HER2-targeted therapies for HER2-positive metastatic breast cancer[J].Cancer Am Cancer Soc,2020,126(19):4278-4288.
3 Goldhirsch A,Ingle J,Gelber R,et al.Thresholds for therapies:highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009[J].Ann Oncol,2009,20(8):1319-1329.
4 Kreutzfeldt J,Rozeboom B,Dey N,et al.The trastuzumab era:current and upcoming targeted HER2+ breast cancer therapies[J].Am J Cancer Res,2020,10(4):1045-1067.
5 Lambert J,Morris C.Antibody-drug conjugates(ADCs)for personalized treatment of solid tumors:a review[J].Adv Ther,2017,34(5):1015-1035.
6 Peddi P,Hurvitz S.Trastuzumab emtansine:the first targeted chemotherapy for treatment of breast cancer[J].Future Oncol,2013,9(3):319-326.
7 Corrigan P,Cicci T,Auten J,et al.Ado-trastuzumab emtansine:a HER2-positive targeted antibody-drug conjugate[J].Ann Pharmacother,2014,48(11):1484-1493.
8 Amiri-Kordestani L,Blumenthal G,Xu Q,et al.FDA approval:Ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer[J].Clin Cancer Res,2014,20(17):4436-4441.
9 Junttila T,Li G,Parsons K,et al.Trastuzumab-DM1(T-DM1)retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer[J].Breast Cancer Res Treat,2011,128(2):347-356.
10 Le X,Claret F,Lammayot A,et al.The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition[J].J Biol Chem,2003,278(26):23441-23450.
11 Barok M,Isola J,Palyi-Krekk Z,et al.Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance[J].Mol Cancer Ther,2007,6(7):2065-2072.
12 Lewis Phillips G,Li G,Dugger D,et al.Targeting HER2-positive breast cancer with trastuzumab-DM1,an antibody-cytotoxic drug conjugate[J].Cancer Res,2008,68(22):9280-9290.
13 Ritchie M,Tchistiakova L,Scott N.Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates[J].Mabs,2013,5(1):13-21.
14 Hamblett K,Jacob A,Gurgel J,et al.SLC46A3 is required to transport catabolites of noncleavable antibody maytansine conjugates from the lysosome to the cytoplasm[J].Cancer Res,2015,75(24):5329-5340.
15 Barok M,Joensuu H,Isola J.Trastuzumab emtansine:mechanisms of action and drug resistance[J].Breast Cancer Res,2014,16(2):209.
16 Krop I,Beeram M,Modi S,et al.Phase I study of trastuzumab-DM1,an HER2 antibody-drug conjugate,given every 3 weeks to patients with HER2-positive metastatic breast cancer[J].J Clin Oncol,2010,28(16):2698-2704.
17 Burris H,Rugo H,Vukelja S,et al.Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2(HER2)-positive breast cancer after prior HER2-directed therapy[J].J Clin Oncol,2011,29(4):398-405.
18 Miller K,Diéras V,Harbeck N,et al.Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive,locally advanced,or metastatic breast cancer[J].J Clin Oncol,2014,32(14):1437-1444.
19 Hurvitz S,Dirix L,Kocsis J,et al.Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer[J].J Clin Oncol,2013,31(9):1157-1163.
20 Verma S,Miles D,Gianni L,et al.Trastuzumab emtansine for HER2-positive advanced breast cancer[J].N Engl J Med,2012,367(19):1783-1791.
21 Diéras V,Miles D,Verma S,et al.Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer(EMILIA):a descriptive analysis of final overall survival results from a randomised,open-label,phase 3 trial[J].Lancet Oncol,2017,18(6):732-742.
22 Krop IE,Kim SB,González-Martín A,et al.Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer(TH3RESA):a randomised,open-label,phase 3 trial[J].Lancet Oncol,2014,15(7):689-699.
23 Krop IE,Kim SB,Martin AG,et al.Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer(TH3RESA):final overall survival results from a randomised open-label phase 3 trial[J].Lancet Oncol,2017,18(6):743-754.
24 Perez E,Barrios C,Eiermann W,et al.Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive,advanced breast cancer:primary results from the phase III MARIANNE study[J].J Clin Oncol,2017,35(2):141-148.
25 Montemurro F,Delaloge S,Barrios C,et al.Trastuzumab emtansine(T-DM1)in patients with HER2-positive metastatic breast cancer and brain metastases:exploratory final analysis of cohort 1 from KAMILLA,a single-arm phase IIIb clinical trial[J].Ann Oncol,2020,31(10):1350-1358.
26 Von Minckwitz G,Huang C,Mano M,et al.Trastuzumab emtansine for residual invasive HER2-positive breast cancer[J].N Engl J Med,2019,380(7):617-628.
27 Wedam S,Fashoyin-Aje L,Gao X,et al.FDA approval summary:ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer[J].Breast Cancer Res,2020,26(16):4180-4185.
28 Mamounas E,Untch M,Mano M,et al.Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer:subgroup analyses from KATHERINE[J].Ann Oncol,2021,32(8):1005-1014.
29 Tolaney S,Tayob N,Dang C,et al.Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer(ATEMPT):a randomized clinical trial[J].J Clin Oncol,2021,39(21):2375-2385.
30 Krop I,Im S,Barrios C,et al.Trastuzumab emtansine plus pertuzumab versus taxane plus trastuzumab plus pertuzumab after anthracycline for high-risk human epidermal growth factor receptor 2-positive early breast cancer:the phase III KAITLIN study[J].J Clin Oncol,2022,40(5):438-448.
31 Hurvitz SA,Martin M,Symmans WF,et al.Neoadjuvant trastuzumab,pertuzumab,and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer(KRISTINE):a randomised,open-label,multicentre,phase 3 trial[J].Lancet Oncol,2018,19(1):115-126.
32 Hurvitz S,Martin M,Jung K,et al.Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2-positive breast cancer:three-year outcomes from the phase III KRISTINE study[J].J Clin Oncol,2019,37(25):2206-2216.
33 Clark A,Yau C,Wolf D,et al.Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2(+)breast cancer in the adaptively randomized I-SPY2 trial[J].Nat Commun,2021,12(1):6428.
34 Patel T,Ensor J,Creamer S,et al.A randomized,controlled phase II trial of neoadjuvant ado-trastuzumab emtansine,lapatinib,and nab-paclitaxel versus trastuzumab,pertuzumab,and paclitaxel in HER2-positive breast cancer(TEAL study)[J].Breast Cancer Res,2019,21(1):100.
35 Harbeck N,Gluz O,Christgen M,et al.De-escalation strategies in human epidermal growth factor receptor 2(HER2)-positive early breast cancer(BC):final analysis of the west German study group adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early BC HER2-and hormone receptor-positive phase II randomized trial-efficacy,safety,and predictive markers for 12 weeks of neoadjuvant trastuzumab emtansine with or without endocrine therapy(ET)versus trastuzumab plus ET[J].J Clin Oncol,2017,35(26):3046-3054.
36 Komlodi-Pasztor E,Sackett D,Wilkerson J,et al.Mitosis is not a key target of microtubule agents in patient tumors[J].Nat Rev Clin Oncol,2011,8(4):244-250.
37 Mittendorf E,Wu Y,Scaltriti M,et al.Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes[J].Clin Cancer Res,2009,15(23):7381-7388.
38 Sakai H,Tsurutani J,Iwasa T,et al.HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine(T-DM1)in patients with HER2-positive metastatic breast cancer[J].Breast Cancer,2018,25(5):605-613.
39 Ozkavruk Eliyatkin N,Aktas S,Ozgur H,et al.The role of p95HER2 in trastuzumab resistance in breast cancer[J].J BUON,2016,21(2):382-389.
40 Filho O,Viale G,Stein S,et al.Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer:phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab[J].Cancer Discov,2021,11(10):2474-2487.
41 Sabbaghi M,Gil-Gómez G,Guardia C,et al.Defective cyclin B1 induction in trastuzumab-emtansine(T-DM1)acquired resistance in HER2-positive breast cancer[J].Clin Cancer Res,2017,23(22):7006-7019.
42 Kovtun Y,Audette C,Mayo M,et al.Antibody-maytansinoid conjugates designed to bypass multidrug resistance[J].Cancer Res,2010,70(6):2528-2537.
43 Kavallaris M.Microtubules and resistance to tubulin-binding agents[J].Nat Rev Cancer,2010,10(3):194-204.
44 Loganzo F,Tan X,Sung M,et al.Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments[J].Mol Cancer Ther,2015,14(4):952-963.
45 Sung M,Tan X,Lu B,et al.Caveolae-mediated endocytosis as a novel mechanism of resistance to trastuzumab emtansine(T-DM1)[J].Mol Cancer Ther,2018,17(1):243-253.
46 Rios-Luci C,Garcia-Alonso S,Diaz-Rodriguez E,et al.Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity[J].Cancer Res,2017,77(17):4639-4651.
47 Li G,Guo J,Shen B,et al.Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells[J].Mol Cancer Ther,2018,17(7):1441-1453.

[1]	王星涵, 吕雅蕾. 曲妥珠单抗耐药机制及HER2阳性乳腺癌耐药后的治疗策略[J]. 实用肿瘤学杂志, 2022, 36(5): 445-451.
[2]	韩淑玲, 姚洋, 刘超, 张艳桥. 肠道微生物影响结直肠癌化疗疗效的研究现状[J]. 实用肿瘤学杂志, 2021, 35(5): 476-479.
[3]	杨思琦,宋启斌,李清清(综述),姚颐(审校). 靶向抑制FGFRs信号在治疗恶性肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 73-77.
[4]	王元综述, 孙轶华审校. β-连环蛋白在软组织肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(5): 455-459.
[5]	侯阳明, 徐颖娟综述, 崔云甫审校. 干扰素调节因子-4结合蛋白与癌症的相关研究进展[J]. 实用肿瘤学杂志, 2017, 31(1): 93-96.
[6]	黄东宁¹, 梁小娜²综述, 陈罡²审校. 长链非编码RNA在结直肠癌中的研究进展[J]. 实用肿瘤学杂志, 2015, 29(3): 263-266.
[7]	乔杰,鲁才杰综述,张庆余审校. Notch3在肿瘤发生发展中的作用[J]. 实用肿瘤学杂志, 2014, 28(5): 451-455.
[8]	吕俊杰, 陶秀娟. CIK治疗恶性肿瘤的基础与临床研究[J]. 实用肿瘤学杂志, 2012, 26(4): 373-376.
[9]	王晓彬, 白析玮, 才丽平. 中药抗卵巢癌分子机制研究进展[J]. 实用肿瘤学杂志, 2011, 25(2): 171-174.
[10]	任民柱, 杨留勤. 骨桥蛋白在肿瘤转移中的作用及机制[J]. 实用肿瘤学杂志, 2010, 24(2): 186-189.
[11]	蒋丽媛, 姜达. 胃癌顺铂耐药机制的研究进展[J]. 实用肿瘤学杂志, 2010, 24(2): 194-197.